Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

CytoDyn CC (Auto) Transcript July 30, 2019 with c

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154898
(Total Views: 897)
Posted On: 08/21/2019 4:32:14 AM
Avatar
Posted By: trding
Re: misiu143 #6350
CytoDyn CC (Auto) Transcript July 30, 2019 with comments from Drs. Sacha, Patterson and Lalezari.
https://78449.themediaframe.com/dataconf/prod...ndexl.html
00:00 greetings and welcome to the CytoDyn
00:01 investment community conference
00:03 call at this time all participants are
00:05 in a listen-only mode a
00:06 question-and-answer session will follow
00:08 the formal presentation as a reminder
00:11 you may submit your questions at any
00:12 time by using the ask a question box on
00:15 the webcast on the left side of your
00:16 screen if anyone should require operator
00:18 assistance during the conference please
00:20 press star 0 on your telephone keypad as
00:22 a reminder this conference is being
00:24 recorded it is now my pleasure to
00:26 introduce your host Michael Mulholland
00:28 chief financial officer thank you sir
00:30 you may begin hello everyone and thank
00:33 you for joining us today this is Michael
00:35 Mulholland chief financial officer of
00:38 sighted I'm joining us on today's call
00:42 is our president and CEO Dr. Nader Pourhassan
00:45 as well as dr. Jonas Sasha dr.
00:48 Bruce Patterson and dr. Jacob Lalezari
00:51 Ari before we begin it is essential that
00:55 we provide you with important cautionary
00:57 language related to certain federal
00:59 securities laws our remarks during
01:03 today's conference call will include
01:05 forward-looking statements
01:07 forward-looking statements are not
01:09 guarantees of future performance and
01:11 involve known and unknown risks
01:13 uncertainties and other factors that are
01:16 difficult to predict actual results may
01:20 be materially different from any future
01:22 results expressed or implied by such
01:25 forward-looking statements these risks
01:28 and uncertainties include among other
01:30 matters statements regarding LaRhonda
01:33 mobs potential efficacy in certain
01:36 immunology and oncology indications the
01:40 company's ongoing ability to raise
01:42 additional new capital that clinical
01:45 trials may not commence or proceed and
01:47 planned products that appear promising
01:50 in early trials may not subsequently
01:52 prove to be viable on safety or efficacy
01:56 Grim's products may not receive
01:59 regulatory approval or market acceptance
02:02 competition may reduce the commercial
02:05 potential of our products we may
02:07 experience product recalls manufacturing
02:09 issues or product liability and our
02:12 patents may be challenged or
02:14 unenforceable
02:16 although forward-looking statements
02:18 helped to provide complete information
02:20 about the company forward-looking
02:22 statements may be less reliable than
02:25 historical information the company
02:27 undertakes no obligation to update
02:29 publicly these forward-looking
02:31 statements except as required by law
02:34 please refer to our recent quarterly and
02:37 annual reports filed with the Securities
02:38 and Exchange Commission for more
02:41 information about the risks and
02:43 uncertainties that could cause actual
02:45 results to differ materially versus our
02:49 current expectations I will now turn the
02:52 call over to dr. Lorenson not thank you
02:56 Mike thank you everyone for
02:59 participating in today's shareholder
03:01 conference called in today's update
03:04 called we have invited three of our
03:06 advisors to speak to you so our
03:09 shareholders could hear directly from
03:11 them their professional opinion about
03:14 Leronlimab and its potential role in
03:16 future of HIV and cancer therapy our
03:20 first invitee is dr. Jonas Sasha
03:23 recently cited I had named dr. Jonas
03:27 OSHA as its senior science advisor to
03:29 explore leronlimab probe on 4e
03:32 potentials in HIV pre exposure
03:35 prophylaxis and cure
03:38 dr. Sascha is an expert in hiv/aids
03:41 research who served on the National
03:44 Institute of Health offices of AIDS
03:48 research Advisory Council and leads a
03:50 research laboratory in the vaccine and
03:53 gene therapy Institute and Oregon
03:55 National Primate Research Center at the
03:57 Oregon Health and Science University
03:59 OHSU the social laboratory aims to
04:03 identify novel therapeutic approaches
04:07 for us for use in prophylactic HIV
04:11 vaccines and HIV remission
04:13 including treatment to this effect dr.
04:17 sasha has been working with leronlimab
04:19 for about a year and his preclinical
04:22 studies produce some very exciting
04:26 results he's the person that lead that
04:29 led the collaboration between citation
04:31 and size Red Cross and those discussion
04:34 led to SATA dine and red tie Red Cross
04:37 signing a Memorandum of Understanding
04:40 for prevention study and we announced
04:42 that currently dr. sasha is a professor
04:45 at the vaccine and gene therapy
04:47 Institute dr. Salk would you please
04:50 explain to our shareholders the Cure and
04:53 prep potential that you see for our
04:56 shareholders dr. Sasha go ahead please
05:00 right thank you for that introduction
05:02 another so I'm excited to officially
05:05 join CytoDyn because I firmly believe
05:08 the future applications of Miranda
05:09 mapped HIV pre exposure prophylaxis or
05:12 prep and HIV cure is both well grounded
05:15 in the basic biology of HIV and it's
05:18 also clinically relevant with the direct
05:19 path into patients these two
05:22 characteristics I believe augur very
05:23 well for the future of leronlimab and
05:25 HIV prep and cure applications I'll
05:28 begin by discussing the application of
05:31 prep pre-exposure prophylaxis so in the
05:34 absence of a prophylactic HIV vaccine
05:36 HIV prep is the best weapon we have for
05:38 slowing the spread of the epidemic
05:40 so adherence the current regimens which
05:42 currently are daily oral antiretroviral
05:45 drugs and the uptake of those regimens
05:47 are the most critical barriers to ruling
05:49 out prep worldwide according to surveys
05:52 of high-risk individuals of men who have
05:54 sex with men approximately 25% of them
05:57 cite the inability to take oral
05:59 antiretroviral drugs daily as a reason
06:01 for their failure to adhere to the
06:02 regimens so the individuals that are at
06:05 high risk of HIV acquisitions are want
06:09 long-acting which we define as once a
06:12 week our greater prep agents and
06:14 currently their dose of leronlimab
06:16 which is once weekly subcutaneous
06:18 administration would fill a major gap in
06:20 prep we also believe that we can extend
06:22 this to further than once once weekly
06:25 the science really
06:27 we're on the map WordPress so mucosa
06:29 Lior look all sexually transmitted HIV
06:31 is always ccr5 tropic that means the HIV
06:35 that is transmitted from when it should
06:37 be infected individual to the other
06:38 always uses the ccr5 co-receptor it's
06:41 well established in the literature that
06:43 individuals are deficient for the ccr5
06:45 molecule the so called ccr5 Delta 32
06:48 mutation are resistant to sexual
06:51 transmission of HIV with no documented
06:53 cases so therefore we in the field of
06:55 HIV research refer to CCR thought as the
06:57 gatekeeper of sexual transmission of HIV
07:00 in my laboratory State we have shown
07:02 that leronlimab effectively converts cd4
07:04 t-cells these are the targets of HIV
07:06 into ccr5 decisions that is they appear
07:09 as if they have come from the individual
07:11 with the ccr5 Delta 32 mutation because
07:14 the basic science of ccr5 and sexual
07:16 transmission and our results to date
07:19 others in the sealed I began to
07:21 recognize the potential for leronlimab
07:22 in prep my lab has received an NIH
07:25 National Institutes of Health grant to
07:27 test the hypothesis of the leronlimab as
07:30 pre exposure prophylaxis in preclinical
07:31 studies in non-human primates and when
07:35 we approached the Thai Red Cross they
07:36 eagerly agreed to initiate a clinical
07:38 trial in Bangkok which has one of the
07:40 highest rates of sexual transmission in
07:42 the world so the seeds that we're sewing
07:44 now I believe will bear service in the
07:46 next year as results of our preclinical
07:48 non-human primate study has become
07:50 published and we commence with the
07:52 clinical work in Bangkok for HIV chor I
07:56 believe leronlimab is also well founded
07:59 in the science fear such a date there
08:01 have been two individuals HIV positive
08:03 individuals who have been functionally
08:04 cured of HIV the so-called Berlin and
08:06 London patients there's also a third
08:09 patient called the essent patient who
08:11 has not yet been published all three of
08:13 these individuals received stem cell
08:14 transplants from ccr5 Delta 32 donors
08:17 so these are donors to lack the ccr5
08:19 molecule
08:20 thus it is currently believed in the HIV
08:22 field that ccr5 deficiency holds the key
08:24 to HIV cure as I mentioned earlier
08:27 Leronlimab administration effectively
08:29 converts cells in a patient's into the
08:30 ccr5 Delta 32 phenotype my laboratory
08:34 has established the only preclinical
08:35 non-human primate model of stem cell
08:37 transplantation we are currently testing
08:39 around the map as an ability to cure
08:41 these animals in stem cell
08:43 transplantation and based upon a results
08:46 in the science funding agencies are
08:48 eager to support both our preclinical
08:50 work and begin initiating human clinical
08:52 trials so specifically as far which is
08:55 the American Foundation for AIDS
08:56 research actually funded the London
08:58 patient work have already verbally
09:00 expressed extremely high interest in
09:02 funding both of these studies both the
09:03 preclinical and the clinical I'm flying
09:05 to New York City on Friday to complete
09:07 these initial conversations the stem
09:09 cells transplant physician that multiple
09:11 Institute's including the University of
09:12 Medicine where the third currently
09:14 unpublished individual is cured wish to
09:16 lead these clinical studies with
09:17 leronlimab so initially the wrong
09:19 level we use in conjunction with stem
09:21 cell transplantation but the future of
09:23 this is the foundation for any therapy
09:25 aimed at HIV cure the biggest example of
09:28 this is Sangamo in their ccr5 editing
09:31 program I believe that ccr5 should lay
09:33 the foundation for all HIV cure
09:35 approaches and based on this I think the
09:37 future is extremely bright from around
09:39 leronlimab in both HIV prep and HIV - thank
09:43 you not her thank you so much dr. Sasha
09:46 just in that regard I want to say one
09:49 word that the prep there which is the
09:53 prevention of people getting HIV when
09:55 they are at high risk of HIV currently
09:58 so is telling there is a product out
10:00 there for prep which is true water is
10:03 currently we have data that says that
10:06 there was one hundred thirty six
10:09 thousand individual uses for $20,000 per
10:12 year that's the cost that's about 2.6
10:15 billion dollars so this is a very
10:17 important aspect of our product that
10:20 we're going to go forward and explore
10:22 our next invitee is dr. Jacob Lalezari
10:27 is doctored dollars are you on the call
10:29 yet yes hi Nana okay so I'm gonna just a
10:33 few words dr. Lalezari is our
10:37 principal investigator for our mono
10:39 therapy and he was involved in our
10:41 combination we started our monotherapy
10:44 five years ago with dr. Lalezari and he
10:47 wrote the very first patients he
10:49 immediately called me and said
10:50 you don't need to enroll anymore
10:53 and I had
10:53 said that to all the shareholders he
10:55 said that the mono therapy is
10:58 well-liked by the patients in that area
11:00 and he will enroll all 40 patients
11:02 himself and he did he's also known at
11:05 the key opinion leaders physicians for
11:09 the world of HIV dr. Lalezari was also
11:11 very excited about the potential use of
11:14 Leronlimab in the world of chance
11:16 and accepted to inject patient in triple
11:19 negative breast cancer study and
11:21 therefore we have allowed triple
11:23 negative breast cancer patients that are
11:25 not naughty patients to enter into tnbc
11:29 therapy with literally map with either
11:31 compassionate protocol or expanded
11:35 access so without any more I'm gonna
11:38 lift off the loaded area name Jay go
11:41 ahead please sure well I'll start with
11:44 the latter scenario because that's I
11:46 think very new and exciting like others
11:49 I've seen the work that Richard had done
11:52 showing that ccr5 was a integral part of
11:56 breast cancer invasion and metastasis
11:58 and we were excited about the triple
12:01 negative breast cancer study but found
12:03 it very difficult to find women who were
12:06 naive in the metastatic setting and so
12:09 we had a referral last week voluminous
12:12 on third line therapy with triple
12:15 negative breast cancer and we've called
12:17 the FDA and applied for an emergency
12:20 treatment IND and we're sending off her
12:23 tissue for confirm her or ccr5
12:26 positivity and then we'll start her on
12:28 treatment and which leads to a broader
12:31 conversation I think was I designed
12:32 about the original protocol being set up
12:35 to both demonstrate perusal concept and
12:39 create a pathway for approval whereas I
12:41 think it might be easier for us if we
12:43 focus on showing proof of concept and
12:47 once we demonstrate that leronlimab is
12:49 is is active in breast or perhaps
12:52 prostate or colon then leading the
12:57 approval protocols for a little bit
12:59 further down the road sorry the first
13:01 order of business is to get the drug
13:03 into patients who need it and show that
13:05 it works and I'm pleased to report
13:07 that the first such patient should be
13:09 starting soon in terms of HIV I guess
13:14 that's all those will neither say that
13:17 we could enroll the full study but it is
13:19 certainly true that in San Francisco we
13:21 it's been an easy sell
13:23 to offer patients once a week cept once
13:26 a week therapy I think that's what
13:27 everyone needs to sort of how to frame
13:30 this it's not sub-q it's it's once a
13:33 week and there are a lot of reasons why
13:34 people want to switch from daily oral
13:37 therapy to once a week therapy some of
13:40 its side effects some of its pill
13:42 fatigue some of its chaotic lifestyles
13:45 but it's not all patients but it is a
13:48 solid ten to fifteen percent of the
13:50 population and I think we'd probably
13:52 enrolled 150 patients now from a tour
13:55 over the years and it you know obviously
13:58 does not work in everybody there are
14:00 some questions as to why it's not
14:02 working in everybody because we're not
14:04 seeing resistance we're not seeing
14:06 co-receptor shifting we're not seeing an
14:09 t drug antibody some of the problems may
14:12 be occurring early because we're not
14:14 overlapping with the ARB long enough to
14:17 go through five half-lives
14:20 of the antibody some of it is that
14:23 patients get six the later on in
14:26 treatment and they have us what appears
14:29 to be an increase or up calculation of
14:31 ccr5 receptor expression that we'll get
14:34 to that with the next speaker but it's
14:37 now working in the great majority of
14:39 patients and I think the data I would
14:41 support over 90%
14:43 once you get past week 12 and I think
14:46 the what I could contribute to this
14:48 conversation is just the observation
14:50 that the patients who do well on leronlimab
14:54 mono therapy love it and
14:57 whatever reason drove them into the
15:00 study obviously they got what they
15:02 wanted and then when it works are quite
15:04 happy but it's been a life changer for
15:08 patients that we have some of them have
15:10 been on this mono therapy now for five
15:12 years or more we don't see any concern
15:17 around injection site reactions I don't
15:20 see any at
15:21 all really safety or toxicity which is
15:24 partly why I'm excited about the breast
15:26 cancer study because if it works there
15:28 it's going to contribute some benefit
15:31 without adding any additional toxicity
15:34 or other issues so the patients do well
15:37 along the mouth is mono therapy for HIV
15:39 love it
15:40 I'm glad to see that the FDA is working
15:44 with high design to try and figure out
15:45 how both to help them cross the finish
15:49 line for their approval in the salvage
15:52 of the treatment experience population
15:55 and obviously they've given a fast track
15:58 designation and they are engaging
16:01 cytodyn in conversation as to what a
16:02 phase 3 mono therapy study would
16:04 look like in the meantime I've been also
16:07 talking with a variety of other
16:10 potential partners for CytoDyn
16:12 because I think if we had a two drug
16:14 regimen that was a two drug once a week
16:17 regimen it would be a killer and it
16:20 would do very well and would be a huge
16:22 benefit to the HIV community and I think
16:25 other sponsors are waking up to that
16:27 idea I think there's a lot of interest
16:30 in monthly intramuscular
16:33 injections but the reality of what's
16:35 involved with patients having to go to
16:38 an office or a pharmacy and painful
16:41 monthly injection is setting in and
16:44 there are a variety of potential
16:46 compounds now that CytoDyn could
16:48 partner with I think there's a model of
16:51 therapy it's good I think there's a
16:53 combination when the second drug it
16:54 could be great um and I'll just stop
16:58 there yep thanks so much
17:00 any questions yeah we were going to go
17:03 okay we're on thank you so much I'm very
17:06 excited to hear a key opinion leader
17:08 telling or shareholder it's really big
17:10 it's huge it's a killer it's always been
17:13 me saying that so I'm appreciative of
17:16 you saying that the next invitee is dr.
17:19 Bruce Patterson dr. Bruce Patterson
17:21 medical doctor former medical director
17:24 of biology at Stanford University
17:26 Hospitals and Clinics
17:27 he's also the CEO and founder of in cell
17:31 BX
17:32 Inc and a top expert
17:34 in ccr5 he has revealed that through
17:37 certain laboratory tests looking at the
17:40 genetics and expression of CCR permanent
17:43 in individual patients sided I'm a more
17:47 closely match the most effective dose
17:50 for each HIV monitored application to
17:53 achieve viral suppression cytodyn also
17:56 signed an agreement to sell pro 140 non
17:59 commercial grade to insert the for
18:02 diagnostic use dr. Patterson will now
18:05 say a few words about this receptor
18:07 occupancy test that he developed for us
18:10 and our definitive agreements that we
18:13 just signed with his lab dr. Patterson
18:15 please go ahead thank you a lot nodded
18:19 in it and again it's my pleasure to be
18:22 talking about this very exciting
18:24 compound having worked with ccr5 since
18:28 the mid 1990s and I'm also excited to
18:33 hear from the other speakers and
18:35 embellish what they both said about the
18:39 clinical utility of leronlimab and
18:43 planned or pro 140 starting in the 1990s
18:48 when we first discovered ccr5 was a
18:51 co-receptor of HIV my laboratory
18:54 published the first work on the
18:56 distribution of ccr5 both on cells and
19:00 tissues and related to what dr. Sasha
19:03 said we were the first to find that ccr5
19:07 was the major co-receptor in the female
19:10 genital tract and responsible for the
19:14 majority of male to female transmission
19:17 coming through the ccr5 receptor the
19:21 same can also be true for mother to baby
19:24 transmission of HIV which it was also
19:28 ccr5 driven but most importantly our
19:33 work from the mid-1990s she really
19:36 showed what are the
19:38 factors have involved the expression of
19:40 ccr5 in the surface of cells because
19:43 that's where the drug is binding and
19:45 blocking the path of the virus into new
19:49 immune cells and we found some very
19:52 interesting things about ccr5 number one
19:55 as Nader mentioned what's the genetics
20:00 ccr5 comes in two different forms a
20:03 wild-type form and a mutated form the
20:06 patients with mutated forms expressed
20:08 less ccr5 and therefore would require
20:11 less drug for an equivalent response
20:17 against against HIV the other important
20:20 factor is that ccr5 is is a highly
20:23 regulated protein many patients have
20:27 different levels on their cells that
20:29 level on immune cells can be affected by
20:33 infections other inflammation other
20:37 illnesses so it's extremely important to
20:41 be able to know how much ccr5 is
20:44 expressed on the surface of the cells
20:47 that get infected by HIV on a patient by
20:50 patient basis and what's really exciting
20:53 is a much like cancer we're bringing
20:56 personalized medicine to infectious
20:58 disease testing and in particular HIV
21:01 therapy and so with this suite of assays
21:05 that we've developed both ccr5
21:07 genotyping we know the genetic type of
21:10 ccr5 at the patients have and they
21:13 receptor occupancy assay which is now up
21:16 and going strong we know exactly how
21:19 much receptor is being made in each
21:22 individual patients and we can tell you
21:25 by the data that we've looked at so far
21:27 that the patients who have spikes in HIV
21:32 viral loads are the ones that have a
21:35 reduction in receptor occupancy it's not
21:38 due to resistance like in other HIV
21:40 drugs but it's solely
21:42 a balance between whether or not you
21:45 have enough drug to block all the routes
21:47 by which HIV can get into cells and that
21:50 can be monitored the patients can be
21:53 boosted to ensure that all of their
21:56 receptors are blocked in addition we've
22:00 taken a lot of the immunology that we
22:02 were working on in regards to ccr5 in
22:06 the mid 90s and we too have looked at
22:09 cancer in the last five years in terms
22:12 of the markers that are being expressed
22:14 on the immune cells that are attacking
22:16 the cancer and we discovered a few years
22:20 ago that ccr5 is expressed on a on a
22:24 population of immune cells called T
22:28 regulatory cells that inhibit the immune
22:32 response against cancer so there's
22:35 actually a second mega mechanism in
22:37 addition to what dr. Pestell has described
22:40 that may also be a target for leronlimab
22:44 in cancer and that is it can
22:47 inhibit the influx in the movement of
22:51 these T regulatory cells which come in
22:54 to shut off the immune response against
22:57 the tumor in addition to the fact that
23:00 ccr5 is actually expressed on the tumor
23:03 itself as dr. Pestell has had published
23:07 so all told in in in my career of over
23:12 20 years of working with this molecule
23:15 we've seen very dramatic effects both in
23:18 terms of an HIV therapy and more
23:21 recently in terms of a potential cancer
23:24 therapy and now it's not just one Mehcad
23:28 cancer mechanism that it's inhibiting
23:30 but potentially a second cancer
23:33 mechanism as well so I can't tell you
23:36 how excited I am to be working with this
23:40 baby on and dr. Sasha's work we're also
23:43 capable of doing receptor occupancy
23:45 actually in tissues and that goes for
23:48 the cancer applications as well so we're
23:52 very
23:53 excited and we now have a suite of
23:57 Diagnostics to personalize treatment
24:00 with Longo map in a patient by patient
24:03 basis to ensure efficacy and to minimize
24:08 side effects so with that you know I'll
24:13 finish and and I'm always happy to
24:15 answer questions thank you Bruce I
24:17 appreciate it so I will only take few
24:19 more minutes since we have taken some
24:21 time for with our invited guests I
24:24 appreciate them very much the update
24:27 that I have for everybody would be very
24:29 quick number one is that dr. Pestell do
24:33 it CytoDyn now that we are he's not
24:36 no longer with sighted that what would
24:38 happen there's a lot of questions about
24:40 that has became my way and I want to
24:42 address that in regards to triple
24:44 negative breast cancer Dr Massimo Cristofanilli
24:47 is going forward just like
24:50 before and he's our principal
24:52 investigator for that trial he was very
24:54 impressed with the speed that cited and
24:56 had taken an IND through the process of
24:59 FDA he indicated he took many months and
25:02 for them to do such thing and we did it
25:05 in three and a half weeks and we have a
25:07 great relationship dr. Scott Kelly our
25:09 chairman of the board and myself have
25:11 been in touch with him and he's excited
25:13 to continue going forward as fast as he
25:15 can and I will talk a little bit of more
25:17 about that in regards to colon cancer
25:19 dr. John Marshall is the person who has
25:22 been our principal investigator for that
25:23 trial and that that trial is going
25:25 forward great in regards to all the
25:28 animal studies which starts with Nash
25:30 and many others cancer indications I
25:32 will update you in a minute and in
25:34 regards to prognostic test we will be
25:37 also continuing to have our first
25:39 meeting with the FDA in the August 28
25:41 and we will have experts to go with us
25:43 and discuss that with FDA so that's all
25:47 the duties that I want to make sure
25:49 everybody knows that we have have right
25:51 we have right people at the right place
25:53 in the second update is about our most
25:56 important task BLA biologic license
25:59 after
26:00 we just hear heard from FDA that we are
26:04 approved for waivers for blacc for small
26:08 businesses which is about a million
26:09 dollars this morning we also are waiting
26:13 for BLA submission to be the time not
26:17 to be nailed down after we hear from FDA
26:21 525 is accepted by them to go forward
26:24 and the CMC question that we have and we
26:27 believe both of those questions will be
26:29 addressed with a positive result as we
26:32 are negotiating and going back and for
26:33 the FDA right now and I think we could
26:35 have something for everybody very soon
26:37 but other than that if those two
26:39 questions or pause have a positive
26:41 answer we're talking end of September
26:43 sided eyes we'll have a final complete
26:47 BLA submitted this will allow us to
26:49 hopefully have approval first quarter of
26:52 next year and revenue on the second year
26:54 very important task for us in regard to
26:56 third update is about monitoring see
26:59 timeline as we said before the latest
27:02 data we just got is the 95 percent
27:05 responders rate with 525 milligram post
27:08 ten weeks and that's called maintenance
27:11 therapy portion as also we said before
27:15 110 patients reach about a year with
27:18 monitor of these six of those patients
27:20 have reached about three years and for
27:21 his for patients that have which five
27:23 years there are elements that was not
27:25 incorporated in our study which was a
27:27 half life which was the incorrect half
27:29 life based upon that the overlap for a
27:32 portion of our trial was different and
27:34 receptor occupancy chance that dr.
27:36 Patterson just talks about those are
27:38 going to make or design for pivotal
27:40 trials much better than what we have and
27:43 we excited to meet with FDA in September
27:45 and that's a day they have given us for
27:47 face to face for mono therapy the fourth
27:50 update is about triple negative breast
27:52 cancer I want to make sure I don't go
27:54 too fast on this I want to make sure
27:56 everybody understands everybody is
27:58 anticipating when is the first patient
28:00 in triple negative breast cancer doctor
28:03 Jay orders or is just indicated that he
28:05 has the patient that they want to inject
28:08 Compassionate Use Agreement or expanded
28:11 use argument why why not inject the
28:14 patient our current protocol that we
28:16 have because the current protocol
28:18 designed by doctors Massimo Cristofanilli
28:21 has been excellent and he has
28:25 indicated that he likes to enroll naive
28:28 patients what is naive patient well
28:30 these are patients who are triple
28:32 negative breast cancer and have no
28:34 option there have had no treatment zero
28:37 treatment so far so dr Cristofanilli
28:40 believes that if we are able to
28:43 enroll five patients at least and we see
28:46 that there they are not needing a second
28:49 line as quickly as most of the patients
28:51 need which is about four to five months
28:53 that means leronlimab has a great
28:56 effect and we will go to FDA he will
28:59 lead a discussion with FDA in in regards
29:02 to having approval so this is a very big
29:06 deal for us to keep it going the same
29:08 way as it is but then we have triple
29:10 negative breast cancer patients who are
29:11 not on you know naive population there
29:14 in first I mean a second or third or
29:16 fourth line we are injecting those
29:19 patients also and we're asking for
29:21 compassionate user agreements from the
29:23 FDA and we are also having a protocol
29:26 for multiple expanded access in triple
29:28 negative breast cancer we believe the
29:30 first patient could be injected very
29:32 soon on that protocol in regards to
29:34 naive population dr. Cristofanilli has
29:37 indicated that he is very hopeful to
29:40 have that first patient injected and
29:41 hopefully have five patients like that
29:43 very soon so we can go to the FDA so the
29:47 next update is graft-versus-host disease
29:48 we are excited to inject the first
29:51 patient in the new modified protocol in
29:53 September dr. Porter is our main
29:55 principal investigator we have discussed
29:57 that with him and he is excited to get
29:59 that moving forward in regards to colon
30:02 cancer we have received new data with
30:06 our animal study from dr. Daniel Linder
30:09 very exciting new positive data that we
30:13 are using and we are going to talk about
30:16 that in the press treat and what that
30:18 means for
30:18 and we're also going to fight face to
30:21 colon cancer protocol most likely by
30:24 this Friday to the FDA in regard so all
30:27 the animal study that we talked in the
30:29 past which was Nash melanoma pancreatic
30:32 breast prostate colon lung liver and
30:34 stomach cancer nash is the most
30:37 important one of those and we have we
30:40 believe that any company with face to
30:42 nash if you look at them they have a
30:43 market cap of one or one and a half
30:45 billion dollars so it's very crucial for
30:47 us to get a face to green-light from FDA
30:50 in NASH those results should be
30:52 available to us within six to eight
30:54 weeks result that trial is being
30:56 conducted the animal study is being
30:59 conducted at of the Daniel Linda's
31:01 laboratory Cleveland Clinic in regards
31:05 to breast cancer we have
31:07 completed those results and discussed
31:10 them already and we are in triple
31:11 negative breast cancer currently with
31:13 Phase two in regards to colon cancer
31:15 that completed and we are filing Phase
31:18 two and regards to other cancers we are
31:20 talking to Daniel dr. Daniel Linder to
31:22 give us timeline and he has indicated he
31:25 could conduct all of those animals in
31:27 the eighth update would be about
31:29 commercial plan a detailed and
31:32 well-planned commercialization strategy
31:34 will be posted to our website most
31:37 likely either next week or a week after
31:39 we have two different group working on
31:42 our TPP target product profile for combo
31:45 and mono seniors health is one of them
31:48 and they have over 50 form of pseudocode
31:50 that have launched their product through
31:52 them so we believe we are in good hands
31:54 and we're going forward in regards to
31:57 number 9 of updates license agreement we
32:01 have told everybody that we had a
32:02 non-binding term sheet for licensing out
32:07 the cells up for 145 but we were too far
32:10 away from each other and what we have
32:12 done is we negotiated and we went back
32:14 and for our business development dr. Rey
32:17 has done that and
32:19 we believe we're very close to
32:21 agreements this agreement for the first
32:23 quarter of billion dollar what the sales
32:25 of the only map could be perhaps funded
32:29 by another Capital Group and we could
32:32 get significant funding upfront these
32:34 are all if statement that I'm putting
32:36 here because all these kind of
32:38 negotiations takes time and there are
32:40 lots of things that we have to consider
32:42 to make sure that we don't short
32:44 ourselves we are at crucial position
32:46 with this company too many people work
32:50 too much too hard and too many
32:51 shareholder have this everything they
32:53 have for us to go forward with their
32:54 funding us and we got to be very careful
32:57 with that number 10 is strengthening the
33:00 management and the board by bringing
33:03 strong well known individuals to join
33:06 our board and perhaps take senior
33:09 management positions so we hope that our
33:12 remarks today allow the shareholders to
33:14 see and understand the business through
33:17 the eyes of studied and management as
33:19 always we will we will be very honest
33:21 very transparent and clear about our
33:25 goal and potential with that let's go
33:28 ahead go to question and answer thank
33:31 you ladies and gentlemen at this time we
33:33 will be conducting any
33:34 question-and-answer session as a
33:35 reminder you may submit a question via
33:37 the webcast at any time by typing it
33:39 into the ask a question field at the
33:41 left side of your screen if you would
33:43 like to verbally ask your question
33:45 please press star 1 on your telephone
33:46 keypad
33:47 the confirmation will indicate that your
33:49 line is in the question queue you may
33:52 press star 2 if you would like to remove
33:53 your question from the queue for
33:55 participants using speaker equipment it
33:57 may be necessary to pick up your handset
33:59 before pressing the star keys please
34:01 hold while we pull for questions
34:11 our first question comes from the line
34:12 of David Callahan a private investor
34:14 please proceed with your question I not
34:19 her hey Dave how are you
34:22 sterling well this is the second Richard
34:25 that's gone
34:26 is this gonna create a vacuum in any way
34:30 No thank you for asking but I can't
34:33 elaborate on the individual person
34:34 working with us or not but I can't tell
34:36 you when the first time we had separated
34:39 dr. Richard trogir five six years ago I
34:41 was having a lot of fire on me because
34:44 everybody says you let go the first
34:46 scientists you have and we also gave
34:48 back six million dollars of NIH money
34:50 back to NIH at that time I told you and
34:53 many people please trust me as I am
34:56 bringing a group of top people to
34:58 conduct and conduct clinical trials and
35:02 take this product forward and I will not
35:05 drop the ball and I think five years
35:07 taking it they pay their pay so I was 20
35:10 years and going five years speaks for
35:13 itself in regards to dr. Richardson
35:15 still I have nothing but good thing to
35:16 say about him but we cannot talk about
35:18 our situation but thanks for the
35:21 question next please thank you once
35:26 again to ask a question please press
35:28 star 1 on your telephone keypad at this
35:30 time our next question comes from the
35:34 line of Jeff Roni with Boston life
35:36 please proceed with your question thank
35:42 you you know we're all of course a
35:45 little disappointed with the triple
35:49 negative breast cancer you know in terms
35:52 of first injection and just to confirm
35:55 Northwestern still going to lead the
35:57 naive trial absolutely and when when was
36:04 that document signed with Northwestern
36:06 to tie that in is that Bennett Bennett
36:09 been in place for several quarters or is
36:11 it just a recent development when the
36:15 company met many months ago we engaged
36:18 in ok so the I assume there's a you know
36:22 contract that need to be signed so that
36:23 was signed on for
36:24 okay great that's great thank you all
36:30 right thank you so I have to say that
36:33 it's been 40 minutes for this call and
36:35 we perhaps have to take our last
36:37 question why do we have question time
36:39 for the last word we have one more one
36:42 more okay this is the last question
36:43 please go ahead thank you our final
36:46 question comes from Randy Hardy a
36:47 private investor pleased to see with
36:49 your question this is Randy and a couple
36:52 of questions real quick seems like
36:54 there's a lot of balls in the air and
36:56 focusing on getting one thing or the
36:59 other completed is there a strategic
37:02 plan anywhere that has the timelines and
37:04 the milestones that could be shared
37:06 maybe in the website for cited dying
37:10 investor section that the investors
37:13 could log into yeah absolutely we will
37:17 have all those timelines that we have in
37:19 the website I think Mike do you want to
37:21 add something yeah I would also direct
37:23 your attention to the number of updates
37:26 that we provide for our clinical
37:29 milestones as we advance the company
37:32 forward
37:33 I'm a no project manager and I like the
37:36 strategic planning aspect of it with you
37:39 know solid dates and then if we miss a
37:41 date and there you know there's a reason
37:42 that a date was missed so we have sort
37:45 of would be great absolutely yes thank
37:49 you and yes thank you so this concludes
37:52 our call operator we're gonna stop the
37:57 Q&A; and I'm just gonna give the final
38:00 remarks I just want everybody to please
38:04 take a look at what we have we have
38:07 biologic license application that is
38:10 hopefully completed by the end of
38:12 September once we hear back from FDA
38:15 that should be finalized we have
38:17 monotherapy that FDA as you heard dr.
38:19 Jay Lalezari said that we are they're
38:21 working with us dr. Jay Lalezari by the
38:24 way had gone to everyone almost every
38:26 one of those FDA meeting in person so
38:29 he's very much aware of the FDA's
38:31 position with us so monotherapy
38:34 September 28 we will meet with FDA
38:37 and the hopefully finalized or pivotal
38:39 trial for first humanized monoclonal
38:42 antibody wants a week's up to you for
38:44 the world of HIV in regards to triple
38:46 negative breast cancer I couldn't be
38:48 more excited to having these two paths
38:50 for naive versus second or higher line
38:53 therapy patients in regards to colon
38:56 cancer we're in great shape
38:58 and we should be finding the stage to
39:00 protocol in regards to our animal
39:02 studies Nash is extremely exciting the
39:06 situation we have for this disease with
39:09 the only map hopefully and if the
39:10 results are positive we would fire phase
39:12 2 immediately
39:13 we also have other animals phase that
39:16 will initiate in the doctor Linda's last
39:19 very soon and in regards to our
39:21 prognostic test that we talked before
39:23 we're going to be going forward with
39:24 that and with that I cannot thank all
39:26 the shareholders who have brought this
39:28 company there for the last five years to
39:30 the point that we are thank you for your
39:32 time have a great day ladies and
39:35 gentlemen this concludes tonight's all
39:36 the conference again we thank you for
39:37 your participation and you may
39:38 disconnect your lines at this time


(3)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us